Michael Seibel, the CEO of Y Combinator, penned a great post about funding rounds not being milestones (see The Blurb).
From grapeless wine to cowless milk
We mapped out 67 private synthetic biology startups according to their main area of focus. Startups are working to build next-gen pharmaceuticals, fuels, and food products, among many other applications of this transformative technology.
P.S. In NYC for LendIt next month? If you’re a senior strategy, M&A, or investment professional in financial services or a fintech VC/PE investor, we’ve got a couple of spots left at our dinner on March 6th. Request an invite here.